RAS

Marjan signs agreement with Range Developments to launch 3 new luxury properties at Al Marjan Island

Retrieved on: 
Monday, February 5, 2024

RAS AL KHAIMAH, UAE, Feb. 5, 2024 /PRNewswire/ -- Marjan, the master developer of freehold properties in Ras Al Khaimah, has signed an agreement with Range Developments to launch three new exclusive properties on Al Marjan Island, the Northern Emirate's premium tourism, business and investment destination. The distinctive luxury offerings comprising The Beach House, The Beach Residences and Beach Vista will fuel the growth of Ras Al Khaimah's expanding luxury real estate sector.

Key Points: 
  • RAS AL KHAIMAH, UAE, Feb. 5, 2024 /PRNewswire/ -- Marjan, the master developer of freehold properties in Ras Al Khaimah, has signed an agreement with Range Developments to launch three new exclusive properties on Al Marjan Island, the Northern Emirate's premium tourism, business and investment destination.
  • Abdulla Al Abdouli, Chief Executive Officer, Marjan, said: "Our agreement with Range Developments to build three new luxury properties, furthers our goal to redefine the high-end real estate sector at Al Marjan Island.
  • Mohammed Asaria, Joint Managing Director and Member of the Board of Range Developments, Range Developments, added: "We are harnessing our wealth of beachfront development across the world to Ras Al Khaimah and Al Marjan Islands.
  • All the three luxury properties are set to elevate the lifestyle at Al Marjan Island adding to Ras Al Khaimah's draw as a premium tourist and real estate destination.

Marjan signs agreement with Range Developments to launch 3 new luxury properties at Al Marjan Island

Retrieved on: 
Monday, February 5, 2024

RAS AL KHAIMAH, UAE, Feb. 5, 2024 /PRNewswire/ -- Marjan, the master developer of freehold properties in Ras Al Khaimah, has signed an agreement with Range Developments to launch three new exclusive properties on Al Marjan Island, the Northern Emirate's premium tourism, business and investment destination. The distinctive luxury offerings comprising The Beach House, The Beach Residences and Beach Vista will fuel the growth of Ras Al Khaimah's expanding luxury real estate sector.

Key Points: 
  • RAS AL KHAIMAH, UAE, Feb. 5, 2024 /PRNewswire/ -- Marjan, the master developer of freehold properties in Ras Al Khaimah, has signed an agreement with Range Developments to launch three new exclusive properties on Al Marjan Island, the Northern Emirate's premium tourism, business and investment destination.
  • Abdulla Al Abdouli, Chief Executive Officer, Marjan, said: "Our agreement with Range Developments to build three new luxury properties, furthers our goal to redefine the high-end real estate sector at Al Marjan Island.
  • Mohammed Asaria, Joint Managing Director and Member of the Board of Range Developments, Range Developments, added: "We are harnessing our wealth of beachfront development across the world to Ras Al Khaimah and Al Marjan Islands.
  • All the three luxury properties are set to elevate the lifestyle at Al Marjan Island adding to Ras Al Khaimah's draw as a premium tourist and real estate destination.

Alira Health Releases Global Report on Robotic-Assisted Surgery (RAS) in Orthopedic Procedures

Retrieved on: 
Thursday, February 1, 2024

The review examines the current clinical and commercial landscape, including current and expected adoption of robotics for orthopedic procedures, trending market dynamics, and upcoming players and technologies.

Key Points: 
  • The review examines the current clinical and commercial landscape, including current and expected adoption of robotics for orthopedic procedures, trending market dynamics, and upcoming players and technologies.
  • Among its global findings, the review uncovered several key insights:
    RAS is most established in knee replacement procedures with 40.6% of current knee replacement and 52.5% expected in the next five years, followed by hip replacement procedures (30.5%) and spinal fusion procedures (24.4%).
  • “Today’s patients and providers expect less invasive, more cost-effective, and more precise surgical options with quicker recovery times,” said Piergiulio Lauriano, Chief Strategy Officer at Alira Health.
  • This research shows how the industry is responding by developing smaller, more affordable, more specialized, and collaborative-enabling orthopedic robotic systems.

Alira Health Releases Global Report on Robotic-Assisted Surgery (RAS) in Orthopedic Procedures

Retrieved on: 
Thursday, February 1, 2024

The review examines the current clinical and commercial landscape, including current and expected adoption of robotics for orthopedic procedures, trending market dynamics, and upcoming players and technologies.

Key Points: 
  • The review examines the current clinical and commercial landscape, including current and expected adoption of robotics for orthopedic procedures, trending market dynamics, and upcoming players and technologies.
  • Among its global findings, the review uncovered several key insights:
    RAS is most established in knee replacement procedures with 40.6% of current knee replacement and 52.5% expected in the next five years, followed by hip replacement procedures (30.5%) and spinal fusion procedures (24.4%).
  • “Today’s patients and providers expect less invasive, more cost-effective, and more precise surgical options with quicker recovery times,” said Piergiulio Lauriano, Chief Strategy Officer at Alira Health.
  • This research shows how the industry is responding by developing smaller, more affordable, more specialized, and collaborative-enabling orthopedic robotic systems.

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Retrieved on: 
Tuesday, January 30, 2024

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“HUTCHMED”) today announces that the marketing approval of ELUNATE® (fruquintinib) by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer (“CRC”). ELUNATE® is a selective oral inhibitor of vascular endothelial growth factor (“VEGF”) receptors -1, -2 and -3, which play a pivotal role in blocking tumor angiogenesis.

Key Points: 
  • HUTCHMED submitted the application based on the approval of ELUNATE® from the China National Medical Products Administration (“NMPA”) supported with local clinical data.
  • “CRC is the second most common cancer type in Hong Kong with limited effective treatment options available, especially for previously treated metastatic CRC patients,” said Dr Caron Li, Vice President, Oncology and Immunology, Hong Kong and Regional Markets of HUTCHMED.
  • We are excited to bring such meaningful treatment options to the cancer patients in Hong Kong.”
    Fruquintinib will be sold and marketed in Hong Kong by HUTCHMED under the brand name ELUNATE®.
  • Fruquintinib was added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) shortly after FDA approval.

Virtual Incision’s Miniaturized Surgical Robot En Route to the International Space Station for Testing of Long-Range Remote Capabilities

Retrieved on: 
Tuesday, January 30, 2024

Virtual Incision Corporation, the developer of the MIRA Surgical System (MIRA), today announced that spaceMIRA is currently in transit to the International Space Station.

Key Points: 
  • Virtual Incision Corporation, the developer of the MIRA Surgical System (MIRA), today announced that spaceMIRA is currently in transit to the International Space Station.
  • Testing with spaceMIRA on the International Space Station will assess the impact of zero gravity when performing simulated surgical tasks.
  • Learnings about remote surgery could potentially impact healthcare in space and across the globe.
  • The testing with spaceMIRA will tell us more about the future potential of miniRAS as it might be applied to remote surgery applications.”

Astera Labs Unveils PCI Express Cable Solutions that Accelerate Cloud and AI Infrastructure Deployments at Scale

Retrieved on: 
Tuesday, January 30, 2024

Astera Labs, the global leader in semiconductor-based connectivity solutions for cloud and AI infrastructure, today announced the sampling of its Aries PCIe® and CXL® Smart Cable Modules™ (SCM) which provide robust and long reach copper cabling connectivity for GPUs, CPUs, and memory in disaggregated cloud and AI infrastructure.

Key Points: 
  • Astera Labs, the global leader in semiconductor-based connectivity solutions for cloud and AI infrastructure, today announced the sampling of its Aries PCIe® and CXL® Smart Cable Modules™ (SCM) which provide robust and long reach copper cabling connectivity for GPUs, CPUs, and memory in disaggregated cloud and AI infrastructure.
  • Thad Omura, Chief Business Officer, Astera Labs, said, “Active PCIe/CXL cables have emerged as a critical connectivity solution for multi-rack GPU clusters and low-latency memory fabrics for AI infrastructure that has physically out-grown a single rack enclosure.
  • Astera Labs’ full portfolio of Aries SCMs will also include an Active Optical Cable (AOC) solution in the future.
  • Schedule to meet with Astera Labs experts and learn how its PCIe, Ethernet, and CXL solutions are enabling critical connectivity for cloud and AI infrastructure.

Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

Retrieved on: 
Wednesday, January 24, 2024

HAMILTON, BERMUDA, Jan. 24, 2024 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has filed a second provisional patent application with the United States Patent and Trade Office (USPTO) to provide broad coverage of different KRAS mutations in human cancer treatment with nanoparticles comprising the Company’s OligoPhore™ platform and a single siRNA sequence, polyKRASmut. The nanoparticles are developed by Altamira as AM-401.

Key Points: 
  • The second provisional application contains in vitro data confirming the ability of polyKRASmut siRNA to knock down a broad range of KRAS mutations in cancer cell lines.
  • Since polyKRASmut was tested against only a limited number of mutations, it may potentially knock down other, yet untested mutations.
  • “By combining the polyKRASmut siRNA with our OligoPhore platform we can direct its delivery to the tumor and tackle with one single compound many different KRAS mutations.
  • Only recently, the FDA approved the first two treatments for KRAS-driven cancer: sotorasib and adagrasib, two small molecule inhibitors of G12C-mutated KRAS for the treatment of NSCLC.

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

Retrieved on: 
Thursday, January 18, 2024

BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today provided an organizational update outlining key objectives toward advancing the development of its lead targeted oncology assets, IK-930 and IK-595. The Company also announced an organizational streamlining that allows for the reallocation of resources from exploratory research and discovery towards the ongoing targeted oncology clinical programs. These efforts reinforce the Company's dedication to maximize impact and drive advancements in patient-directed treatments for cancer.

Key Points: 
  • The Company also announced an organizational streamlining that allows for the reallocation of resources from exploratory research and discovery towards the ongoing targeted oncology clinical programs.
  • These efforts reinforce the Company's dedication to maximize impact and drive advancements in patient-directed treatments for cancer.
  • “Our extended team has achieved many significant milestones together, and IK-930 and IK-595’s clinical progress is evidence of these collective efforts.
  • Ikena will be forever grateful for the impact that each of the members of our discovery and research team has had.

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Retrieved on: 
Wednesday, January 17, 2024

The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).

Key Points: 
  • The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).
  • “We are progressing our AMP-powered, lymph node-targeted cancer vaccine, ELI-002 7P, as a monotherapy in an adjuvant setting for patients with pancreatic cancer, and recently dosed the first patient in the randomized Phase 2 cohort.
  • AMPLIFY-7P is a Phase 1 and Phase 2 study of ELI-002 7P in patients with RAS mutated pancreatic and colorectal tumors after locoregional treatment.
  • A Phase 2 interim analysis is planned using group sequential design for control of overall alpha 0.10.